Collplant Holdings ( (CLGN) ) has shared an announcement.
CollPlant Biotechnologies reported its 2024 financial results and provided a corporate update on March 26, 2025. The company has made significant progress in its regenerative breast implant program, with promising six-month study results indicating successful tissue integration and vascularization. CollPlant also received a $2 million payment from AbbVie for advancements in their collaboration on dermal fillers. Additionally, the company expanded its distribution network for Vergenix STR in Europe and Asia and implemented a cost-cutting plan, reducing its workforce by 20% to optimize resources. The company’s strategic initiatives and collaborations aim to position it as a leader in regenerative medicine, with a focus on innovative, safe, and effective medical solutions.
More about Collplant Holdings
CollPlant Biotechnologies is a regenerative and aesthetics medicine company based in Israel, specializing in non-animal-derived collagen technologies for tissue regeneration and medical aesthetics. The company focuses on developing innovative products such as regenerative breast implants and dermal fillers, targeting significant market opportunities in the medical and aesthetic sectors.
YTD Price Performance: -26.51%
Average Trading Volume: 8,891
Technical Sentiment Signal: Buy
Current Market Cap: $32.07M
See more data about CLGN stock on TipRanks’ Stock Analysis page.